This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Report Summary

This report addresses patient skin cleansing with chlorhexidine gluconate (CHG) as an effective intervention in the arsenal against surgical site infections (SSIs). It reviews current conversation among experts, looks at various studies in the medical literature, and reviews some best practices related to risk reduction.

Editor's Take

Numerous studies have demonstrated that surgical site infections (SSIs), considered to be the most frequently reported healthcare-associated infection (HAI), are associated with significant patient morbidity and mortality as well as escalating healthcare expenditures annually. Any intervention(s) that can mitigate risk associated with SSIs is another weapon in the arsenal against HAIs. Patient skin cleansing with chlorhexidine gluconate (CHG) is becoming a widely accepted and viable intervention, and has been the focus of researchers' efforts to determine its role in infection rate reduction.

Takeaways for Your Business

  • Review current and forthcoming guidance addressing CHG skin cleansing
  • Learn about the importance of using a standardized regimen for pre-admission patient bathing
  • Explore studies in the medical literature examining the effectiveness of CHG skin cleansing in SSI prevention